Heart failure & cardiomyopathies
Iron Therapy and Severe Arrhythmias in Heart Failure with Reduced Ejection Fraction (HFrEF): Rationale, Study Design, and Baseline Results of the RESAFE-HF Trial
Authors' conclusion
The RESAFE-HF trial is expected to provide evidence on the effect of treating ID with FCM in HFrEF based on real-world data.
Study context
- Population
- Adults with HFrEF, iron deficiency and cardiac implantable electronic devices (CIEDs) scheduled to receive IV ferric carboxymaltose (FCM) in clinical practice
- Participants
- 106 adults
- Outcome
- Composite iron-related endpoint:
- Haemoglobin ≥ 12 g/dL
- Ferritin ≥ 50 ng/L
- Transferrin saturation > 20%
Methodological detailsrationale, design and baseline results, single-centre, open-label, Visits at baseline, 3, 6 and 12 months
- Rationale, design and baseline results
- Single-centre
- Open-label
- Visits at baseline, 3, 6 and 12 months
Main finding
As reported in the abstract
Baseline characteristics
- Median age, years (14.4)
- 72
- Male
- 84.9%
- NYHA II/III
- 92.5%
- Appropriate CIED therapy for ventricular tachyarrhythmia in preceding 12 months
- 19 (17.9%)
- Frequent, repetitive multiform premature ventricular contractions
- 75.5%
Observational data: associations, not effects.
Original publication
Iron Therapy and Severe Arrhythmias in HFrEF: Rationale, Study Design, and Baseline Results of the RESAFE-HF Trial. ESC Heart Fail. Published 17 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →